Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Nature Medicine2005Vol. 11(6), pp. 623–629
Citations Over TimeTop 1% of 2005 papers
Roberto Chiarle, William J. Simmons, Honjying Cai, Girish Dhall, Alberto Zamò, Regina Raz, James G. Karras, David T. Levy, Giorgio Inghirami
Related Papers
- → Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib(2019)15 cited
- → From Pathology to Precision Medicine in Anaplastic Large Cell Lymphoma Expressing Anaplastic Lymphoma Kinase (ALK+ ALCL)(2017)10 cited
- → Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma(2019)7 cited
- → Anaplastic large cell lymphoma, ALK-positive and anaplastic large cell lymphoma ALK-negative(2009)8 cited
- → An Exploration into the Origins and Pathogenesis of Anaplastic Large Cell Lymphoma, Anaplastic Lymphoma Kinase (ALK)-Positive(2017)7 cited